Mehmet Bilen, MD @bilenma @EmoryUniversity @WinshipAtE
Mehmet Asim Bilen, MD from Winship Cancer Institute of Emory University discusses the Evaluation of a novel blood pressure scoring method and its associati
Related Articles
Paolo Tarantino: Recap of the first 40 years of ADC development – OncoDaily
Paolo Tarantino: Recap of the first 40 years of ADC development / AACR25, ADC development, antibody, cancer, Cancer Discovery, drug conjugates, fight against
RAS Inhibitor Resistance in PDAC: Insights from AACR 2025
Explore the challenges of RAS inhibitor resistance in PDAC. Learn how KRAS mutations affect treatment outcomes.
92% RFS at 2 Years: PD-1 Immunotherapy for MMRd / MSI-H Tumors at AACR 2025
Discover the impact of PD-1 immunotherapy on MMRd/MSI-H tumors. Learn about breakthrough results from AACR 2025.
Antibody-Drug Conjugates: 40 Years of Cancer Treatment Innovation
Explore the transformative potential of Antibody-Drug Conjugates in targeted cancer treatments and their impact on precision medicine.
Zongertinib 71% ORR for HER2-Mutant NSCLC: Key Insights from AACR 2025
Explore the impact of Zongertinib HER2-Mutant NSCLC treatment with a 71% response rate in the latest Beamion LUNG-1 trial.
Pembrolizumab KEYNOTE-689 Phase 3 Trial Update for LA-HNSCC at AACR 2025
Get the latest updates from the KEYNOTE-689 study on pembrolizumab and its impact on head and neck squamous cell carcinoma.
FDA Approves Anike / Penpulimab-kcqx for Non-Keratinizing Nasopharyngeal Carcinoma: Key Insights for Oncologists
Get insights on Anike (Penpulimab-kcqx) NPC’s role in first-line treatment and its benefits for patients with nasopharyngeal carcinoma.
Sotorasib / Lumakras + Panitumumab / Vectibix CodeBreaK 300 Shows Promise in KRAS G12C-Mutated Colorectal Cancer
Uncover the groundbreaking insights from the CodeBreaK 300 study on treating chemorefractory KRAS G12C-mutated mCRC.
FDA Approves Opdivo / Nivolumab Plus Yervoy / Ipilimumab for MSI-H/dMMR Colorectal Cancer: A Precision Oncology Milestone
Get informed about Nivolumab MSI-H Colorectal and its FDA approval. Detailed insights from the CHECKMATE-8HW trial await.
Oncology Conferences 2025-2027: Full List & Details
Prepare for Oncology Conferences 2025 to 2027. Join leading meetings such as ASCO and SABCS for the latest in cancer research.